Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Short-term Investments (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Short-term Investments readings, the most recent being $148.4 million for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 24309.87% to $148.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $148.4 million, a 24309.87% increase, with the full-year FY2025 number at $156.6 million, up 25650.99% from a year prior.
  • Short-term Investments hit $148.4 million in Q4 2025 for Enanta Pharmaceuticals, down from $156.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $298.8 million in Q1 2021 to a low of $608000.0 in Q2 2024.
  • Median Short-term Investments over the past 5 years was $179.5 million (2021), compared with a mean of $179.3 million.
  • Biggest five-year swings in Short-term Investments: tumbled 99.8% in 2024 and later skyrocketed 26100.49% in 2025.
  • Enanta Pharmaceuticals' Short-term Investments stood at $160.0 million in 2021, then increased by 7.67% to $172.2 million in 2022, then surged by 72.55% to $297.2 million in 2023, then tumbled by 99.8% to $608000.0 in 2024, then skyrocketed by 24309.87% to $148.4 million in 2025.
  • The last three reported values for Short-term Investments were $148.4 million (Q4 2025), $156.6 million (Q3 2025), and $159.3 million (Q2 2025) per Business Quant data.